Orally administered endoxifen inhibits tumor growth in melanoma-bearing mice

[1]  M. A. Mahr,et al.  First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Rachel A. Kudgus,et al.  Abstract P1-08-03: Identification and characterization of a novel endoxifen substrate, PKCβ1, and its interaction with the estrogen receptor , 2017 .

[3]  S. Sheikh,et al.  Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen , 2016, Clinical and translational science.

[4]  J. Custódio,et al.  Rethinking tamoxifen in the management of melanoma: New answers for an old question. , 2015, European journal of pharmacology.

[5]  P. Limonta,et al.  Estrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines , 2015, PloS one.

[6]  M. Goetz,et al.  Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies , 2014, Cancer Chemotherapy and Pharmacology.

[7]  J. Custódio,et al.  The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells. , 2013, European journal of pharmacology.

[8]  S. Sheikh,et al.  Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects , 2010, Clinical pharmacology and therapeutics.

[9]  S. Sheikh,et al.  Orally administered Endoxifen is a new therapeutic agent for breast cancer , 2010, Breast Cancer Research and Treatment.

[10]  M. Beckmann,et al.  Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. , 2009, JAMA.

[11]  T. Satou,et al.  Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. , 2009, Experimental cell research.

[12]  S. Itami,et al.  Expression of estrogen receptor β in normal skin, melanocytic nevi and malignant melanomas , 2008, The Journal of dermatology.

[13]  L. Nanney,et al.  Oestrogen receptor‐β expression in melanocytic lesions , 2006 .

[14]  T. Skaar,et al.  Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen , 2004, Breast Cancer Research and Treatment.

[15]  T. Reiman,et al.  Use of tamoxifen in the treatment of malignant melanoma , 2003, Cancer.

[16]  K. Rowland,et al.  Phase III clinical trial of the combination of cisplatin, dacarbazine, and carmustine with or without tamoxifen in patients with advanced malignant melanoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Atkins,et al.  Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  C. Boni,et al.  Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. , 1992, The New England journal of medicine.

[19]  C. Karakousis,et al.  Estrogen and progesterone receptors and tamoxifen in malignant melanoma. , 1980, Cancer treatment reports.

[20]  L. Nanney,et al.  Oestrogen receptor-beta expression in melanocytic lesions. , 2006, Experimental dermatology.

[21]  M. Maehr.  New Answers to an Old Question , 1988 .